PM360

SEPTEMBER 21, 2023

Jeff Casberg, MS, RPh, Senior Vice President of Clinical Pharmacy at IPD Analytics, a managed care and pharmaceutical consultancy, highlighted a wide range of 2023 key events that will affect managed care professionals by the end of the year. This product is expected to have three generic launches in 2023.

Management 105

Management Manufacturing Sales Competition 105

MedReps

JANUARY 30, 2023

If you know how to prepare and get ahead of your competition, reaching your goals will be that much easier. Medical Sales Trends to Watch Out For in 2023 If you want to know what the future holds and create some forward-thinking sales goals, then check out these medical sales trends to watch out for in 2023.

Medical sales 74

Medical sales Medical Sales Sales goal 74

European Pharmaceutical Review

NOVEMBER 8, 2022

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. Citizen Petitions before the FDA. 2 Submission of a Citizen Petition to the FDA obligates the regulator to address the arguments raised. 5) monitoring access to biosimilars. Senate Bill 562 (S.

Food and Drug Administration 52

Food and Drug Administration Pharma Prescription Manufacturing 52

Clarivate

JULY 5, 2023

The month of July could see seven FDA-approved adalimumab biosimilars launch in the United States, an unprecedented situation for a market that has been relatively slow to embrace biosimilars. The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. from 91% in 2023 to 36% by 2031.

Marketing 97

Marketing Physicians Manufacturing Competition 97

pharmaphorum

JANUARY 9, 2023

This Nine for 2023 three-part series will argue that, this year, the future-facing Janus prediction of unprecedented and transformative change is true. However, the pandemic is only one of the often deep-rooted forces that will come together in 2023 to exert transformative pressure on healthcare.

Medicine 89

Medicine Healthcare Healthcare Pharma 89

Nixon Gwilt Law

JANUARY 16, 2024

Companies will also need to understand whether the FDA will consider their model to be software as a medical device (SaMD) that is subject to the FD&C Act. Rebecca says, “ New and existing companies will offer GLP-1 prescriptions for weight loss. The field is already saturated, so we will see companies exit as leaders emerge.

Healthcare 52

Healthcare Healthcare Management Insurance 52

Pharmaceutical Technology

DECEMBER 4, 2022

There are seven FDA-approved Humira biosimilars, of which Amgen’s Amjevita will be launched in January. Others are made by big pharma giants like Boehringer Ingelheim , Novartis , or Pfizer , which has raised the expectations for a competitive market. . Humira biosimilars became available in the EU in October 2018.

Marketing 104

Marketing Physicians Competition Patients 104